PIK3CA and breast cancer: Initial attempts to target the PI3K enzyme complex in ER+/HER2− breast cancer using “pan-PI3K inhibitors” that inhibit all four isoforms (α, β, γ, and δ) of the class IA PI3Ks were limited by toxicity [31, 32].